

Providing answers for
cancer patients

curasight

Curasight A/S Year-end report 2025

In this document, the following definitions shall apply unless otherwise specified: "the Company" or "Curasight" refers to Curasight A/S, CVR no. 35249389.

The Company
 CURASIGHT A/S
 Ole Maaløes Vej 3
 2200 København N
 Tel.: 22 83 01 60
 Registered office: København N
 CVR no.: 35 24 93 89
 Financial year: 01.01 - 31.12

Key figures and selected posts

Q4 (2025-10-01 – 2025-12-31)

- Gross loss amounted to kDKK -14,577 (kDKK -10,210)
- Operating loss amounted to kDKK -16,203 (kDKK -11,924)
- Loss before tax amounted to kDKK -16,686 (kDKK -12,334)
- Loss for the period amounted to kDKK -15,311 (kDKK -10,959)
- Total assets amounted to kDKK 50,055 (kDKK 23,688)
- Equity ratio amounted to 37.1% (32.6%)
- Earnings per share amounted to DKK -0.32 (DKK -0.58)

Q1-Q4 (2025-01-01 – 2025-12-31)

- Gross loss amounted to kDKK -49,676 (kDKK -32,731)
- Operating loss amounted to kDKK -55,592 (kDKK -40,367)
- Loss before tax amounted to kDKK -58,730 (kDKK -42,336)
- Loss for the year amounted to kDKK -53,230 (kDKK -36,836)
- Total assets amounted to kDKK 50,055 (kDKK 23,688)
- Equity ratio amounted to 37.1% (32.6%)
- Earnings per share amounted to DKK -1.1 (DKK -1.74)

Numbers in parenthesis are the numbers from the same period in 2024.

Definitions

Equity ratio: Shareholders equity as a proportion of total assets.
 Earnings per share: Profit/Loss for the period divided by average number of shares.

Key milestones during Q4 2025 sets the stage for 2026

The fourth quarter of 2025 marked a strong finish for the year for Curasight with meaningful progress both clinically and financially, as the Company continued to execute on its uPAR-based theranostic strategy and laid the foundations for a milestone-rich year ahead in 2026.

A major milestone during the quarter was the successful dosing of the first patient in the Phase 1 clinical trial of uTREAT® in patients with glioblastoma. This event marked the transition of uTREAT into active clinical execution and is a defining step in realising our vision of a fully integrated radionuclide theranostic platform. By advancing uTRACE® and uTREAT in parallel we aim to deliver improved diagnosis and more targeted treatment for certain types of cancer. The initiation of the Phase 1 trial in glioblastoma marks important progress in our efforts to find a new treatment option for patients with this aggressive cancer, where there are currently very limited treatment options. The trial continues to progress, and the Company remains on track to report top-line data in 2026.

In parallel, uTRACE® continued to build momentum as the diagnostic backbone of our theranostic platform, with the continuation of the Phase 2 trial in prostate cancer under the collaboration with our strategic partner Curium. By the end of 2025, uTRACE® had been evaluated in more than 450 patients across multiple cancer indications. The continued advancement of uTRACE and uTREAT reinforces our belief that the precise targeting of uPAR has the potential to transform patient management by enabling improved diagnosis,

refined patient selection, and more targeted treatment. Importantly, the quarter also saw further strengthening of Curasight's capital base. During 2025, the Company raised a total of DKK 63.4 million in equity and secured DKK 40 million through new and renegotiated debt facilities, significantly enhancing our financial flexibility and ability to execute planned clinical activities and key milestones into 2026.

Against the backdrop of growing global focus on radionuclide theranostics, Curasight enters 2026 at an inflection point. With a clinically validated uPAR-targeted diagnostic, an advancing therapeutic program and a strengthened balance sheet we believe the Company is well-positioned to create long-term value.

As we look forward to the next stage of growth for our company, we remain committed to our focus on disciplined execution, the generation of high-quality clinical data and the evaluation of partnerships and strategic opportunities for the future.

We would like to thank our shareholders for their continued support and look forward to sharing further progress as Curasight advances through this important next stage of development.

Sincerely,

Ulrich Krasilnikoff
 CEO, Curasight A/S

Highlights during fourth quarter and after the period

On October 1, announced issuance of US patent 12,409,240 B2 which expands the protection of the company's uPAR diagnostic platform, uTRACE. The patent term has been extended by 751 days (more than 2 years) so that it now expires in 2035.

On October 29, announced strong momentum in part 2 of the Phase 2 Study as all nine sites across Germany, Sweden and Denmark are now fully activated and recruiting patients.

On November 26, announced that its phase 1 trial investigating uTREAT® for aggressive brain cancer is now open for patient enrollment.


On December 18, announced the successful and safe dosing of the first patient in the Phase 1 trial using uTREAT® in brain cancer (high-grade gliomas). The news marks the initiation of the first clinical trial under the Company's therapeutic platform uTREAT®, investigating it as a potential treatment option for glioblastoma.

On December 29, announced a loan agreement with Fenja Capital II A/S regarding a loan facility. The total facility amounts to DKK 40 million in two tranches, where the first tranche of DKK 25 million is structured as a convertible loan, including DKK 10 million refinancing and DKK 15 million to be disbursed. The second tranche of DKK 15 million may be drawn in Q2 2026. The facility matures on 29 December 2026 and includes a 5 percent setup fee.

On January 5, announced that Curasight participated at the J.P. Morgan Healthcare Conference Week.

On January 12, announced encouraging preliminary data from Phase 1 Trial evaluating First-in-Class radiopharmaceutical uTREAT® in high-grade gliomas.

On February 17, announced that Curasight will present at TD Cowen's 46th Annual Health Care Conference in Boston.



By combining diagnostics with therapy – Curasight is on a mission to improve the lives of millions of people with cancer

Curasight A/S in short

Curasight A/S is a clinical-stage radiopharmaceutical company based in Copenhagen, Denmark, developing uTREAT®, a first-in-class uPAR-targeted radioligand therapy (RLT) platform designed to treat aggressive solid tumors.

The therapeutic platform uTREAT® is validated and supported by uTRACE®, a clinically validated uPAR PET imaging agent built on the same targeting ligand, enabling one-to-one patient selection and biodistribution confirmation under a disciplined theranostic approach.

uTRACE® has been evaluated in nine clinical studies in more than 450 patients across eight solid tumor types, providing a substantial human imaging evidence base for uPAR target engagement and ligand performance. uTRACE® is a fully developed companion diagnostics for uTREAT(R).

The scientific rationale – why uPAR?

uPAR (urokinase-type plasminogen activator receptor) is associated with tumor invasion, angiogenesis, and metastasis and is considered a functional driver of cancer aggressiveness. Curasight's thesis is that uPAR can be used as an "address label" to deliver targeted radiation to clinically relevant tumor biology, rather than attempting to inhibit uPAR signaling through conventional drug modalities.

Rather than being limited to a single tumor type, uPAR is broadly expressed across solid tumors.

This makes uPAR a scalable therapeutic target across multiple aggressive tumor types.

Historically, uPAR has been difficult to exploit using conventional drug modalities. Radioligand therapy uTREAT® reframes the opportunity: instead of blocking uPAR signaling, the receptor can be used as a handle to deliver a payload of radiation directly to aggressive cancer cells and eliminate them.

(Diagnostics) uTRACE®

uPAR PET imaging with uTRACE® for improved imaging of cancer across several cancer types and patient selection and biodistribution confirmation.

uPAR Theranostic

The combination of non-invasive PET imaging (Diagnostic) and uPAR targeted radioligand therapy (Therapy) is together known as Theranostics and where uTRACE® serves as a companion diagnostics for uTREAT®.

(Therapy) uTREAT®

uPAR-targeted radioligand therapy (RLT) designed to deliver a radioactive payload to uPAR-expressing tumor tissue.

Pipeline and clinical focus

uTREAT®: Curasight's lead asset is uTREAT®, a first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat aggressive solid tumors. In December 2025 the first patient was dosed in Curasights Phase 1 trial in glioblastoma (GBM), an aggressive brain cancer with high unmet medical need. The program is designed to generate quantitative insights on biodistribution and dosimetry that can guide subsequent clinical decisions and potential platform expansion. Top line data is expected mid-2026.

Following proof-of-concept in GBM, and subject to clinical data, regulatory feedback and available resources, Curasight intends to evaluate uTREAT® in additional uPAR-expressing solid tumors and may use basket-style clinical strategies to support disciplined indication selection. Indications under consideration include non-small cell lung cancer (NSCLC), neuroendocrine tumors (NET), head and neck cancer, pancreatic cancer, and colorectal cancer.

uTRACE® (imaging) is a supporting asset and operational enabler for the platform. In prostate cancer, uTRACE® is being evaluated under a collaboration signed in 2023 with Curium Pharma. Curasight leads the program and retains all rights to uTREAT® and uTRACE® outside prostate cancer.

Next-generation uPAR ligands: In parallel, Curasight is advancing next-generation uPAR ligands (higher-affinity linear and macrocyclic peptide binders) intended to support future platform expansion and improve uptake at lower target density. Development timelines remain subject to progress.

GMP Manufacturing: Radiopharmaceutical development requires robust clinical and manufacturing execution. Curasight's platform benefits from GMP experience established through uTRACE® clinical use and from a shared ligand strategy across imaging and therapy, which reduces complexity and supports reproducible workflows as clinical development progresses.

The RLT Market

Established theranostic pathways such as PSMA and SSTR2 demonstrate that disciplined target selection, patient stratification and dosimetry driven RLT can create meaningful clinical and economic impact.

Curasights uPAR platform differentiates from marketed RLT's in that it holds the potential to enable one drug to

become a therapy for multiple aggressive tumor types. The theranostic approach makes it highly specific and personalized.

Key facts

- Lead value driver: uTREAT® (uPAR-targeted RLT) – Phase 1 initiated in GBM; first patient dosed in December 2025.
- Supporting asset: uTRACE® (uPAR PET imaging) – evaluated in nine clinical studies (>450 patients) across eight solid tumor types; Phase 2 in prostate cancer led by Curium (collaboration signed in 2023).
- Platform thesis: one target (uPAR) and one targeting ligand enabling therapy-led development with imaging support for patient selection and biodistribution confirmation.
- Scientific origin: based on research conducted at Rigshospitalet and the University of Copenhagen led by Professor Andreas Kjær and collaborators.
- Intellectual property: patent portfolio and pending applications reported by the Company to extend to 2043.

Important information

uTREAT® is an investigational compound. Its safety and efficacy have not yet been established and it has not been approved by any regulatory authority. This section may contain forward-looking statements, including statements regarding clinical development plans and timing; actual results may differ materially due to risks and uncertainties.

About high grade glioma and glioblastoma

Treatment of glioblastoma presents a significant unmet medical need, necessitating innovative and effective treatments. Approximately 65,000 patients in the US and EU are diagnosed annually with brain tumors of which approximately 30,000 patients are diagnosed with high-grade glioma where the prognosis is very poor. Glioblastoma is a rare disease in both markets, qualifying for Orphan Drug Designation; moreover, because of the high unmet need, drug candidates are more likely to qualify for e.g. Priority Review, Breakthrough Therapy Designation, or Accelerated Approval. Approximately 10 % of the patients are children. The prognosis for individuals with glioblastoma is very poor as approximately 50 % of the patients die within 14 months and after five years from diagnosis only 5 % are still alive.

About neuroendocrine tumors

Each year approximately 35,000 new cases are diagnosed in the US and EU. Due to the long survival of these patients, more than 400,000 patients are living with the disease in the US and EU. Neuroendocrine tumors

are a rare form of cancer that occurs in glandular cells most frequently in the lining of the gastrointestinal tract or in the lungs, but the disease can in principle occur in all organs of the body.

About head and neck cancer

Head and neck squamous cell carcinoma is the 6th most common cancer worldwide with 890,000 new cases and 450,000 deaths in 2018. The incidence is anticipated to increase over the coming years.

About Non Small Cell Lung Cancer (NSCLC)

Lung cancer is the leading cause of cancer-related deaths worldwide, accounting for the highest mortality rates among both men and women. NSCLC is the most common type of lung cancer with approximately 700,000 patients being diagnosed each year in the US and EU alone. The 5-year survival rate in the US is around 28 %. Despite advances, there is a need for more effective therapies.

About Pancreatic Cancer

Pancreatic cancer is the 12th most common cancer worldwide. It is the 12th most common cancer in men and the 11th most common cancer in women. There were more than 495,000 new cases of pancreatic cancer in 2020. Pancreatic cancer begins when abnormal cells in the pancreas grow and divide out of control and form a tumor. The pancreas is a gland located deep in the abdomen, between the stomach and the spine. It makes enzymes that help digestion and hormones that control blood-sugar levels. More than 66,000 Americans are expected to be diagnosed with pancreatic cancer in 2024.


About Prostate cancer

Prostate cancer is the most common cancer in men, with approximately 640,000 new cases expected to be diagnosed annually across the US and the EU. While many tumors grow slowly, a significant proportion develop into aggressive disease that is challenging to detect and monitor with existing methods. Accurate detection and monitoring of prostate cancer remain major challenges, particularly in patients with advanced or recurrent disease.

About colorectal cancer

Colorectal cancer (CRC) is among the most common malignancies and remains a major cause of cancer mortality. Approximately ~670,000 patients are diagnosed each year across the US and Europe. Despite effective screening in parts of the population, a substantial fraction of patients are still diagnosed with advanced disease; in the US the overall 5-year relative survival is ~63%, dropping to ~13% for distant (metastatic) disease, underscoring the need for more effective treatments for advanced CRC.


Key clinical milestones 2025-2026



Therapeutic Program



Sponsor: Curasight
 Diagnostic platform: uTRACE® and uTREAT®



*A basket trial is designed to simultaneously evaluate treatments for multiple tumors in a single clinical trial. Curasight will investigate cancer therapy with uTREAT® in selected cancer diseases known to express uPAR.

Partnered Project



Sponsor: Curasight
 Partner: Curium Inc.
 Diagnostic platform: uTRACE®




*) Investigated for diagnostic performance for non-invasive classification of ISUP grades among patients with localised, untreated prostate cancer.
 **) Investigator-initiated study



Investigator Initiated Trials



Sponsor: National University Hospital of Denmark (Rigshospitalet)
Diagnostic platform: uTRACE®



^{*)} Investigator Initiated Trails = IITs, >400 patients have received uTrace in these Investigator Initiated Trials
^{**)} Completed with fewer patients than planned for technical reasons

Financial analyst coverage



Since:
June, 2021

Type:
Commissioned

Frequency:
Continuously

Areas:
Curasight's operations, platforms, markets and competitors

[→ Read more](#)

Since:
May, 2025

Type:
Commissioned

Frequency:
Continuously

Areas:
Curasight's operations, platforms, markets and competitors

[→ Read more](#)

Since:
August, 2021

Type:
Commissioned

Frequency:
Continuously

Areas:
Curasight's operations, platforms, markets and competitors

[→ Read more](#)

Corporate Information

Shareholders

The table below presents the management's shareholdings in Curasight.

Name	Votes & capital (%)
AK 2014 Holding ApS ¹	15,28
UK Curacap ApS ²	11,12
Madsen Holding 2013 ApS ³	1,95
LT 2003 ApS ⁴	1,23
Charlotte Vedel ⁵	0,16
Kirsten Drejer ⁶	0,12
Hanne Damgaard Jensen ⁷	0,07

1. Owned by co-founder, CSO, and Board Member Andreas Kjaer

2. Owned by CEO and Board Member Ulrich Krasinikoff

3. Owned by Co-founder and Director CMC, Jacob Madsen

4. Owned by Deputy Chairman of the Board, Lars Trolle

5. Member of the Board of Directors

6. CDO & COO

7. Chair of the Board of Directors

The share

The shares of Curasight A/S were listed on Spotlight Stock Market on October 8, 2020. The short name/ticker is CURAS, and the ISIN code is DK0061295797. As of December 31, 2025, the number of shares was 47,922,841 (21,148,880). All shares have equal rights to the Company's assets and results.

Long-term incentive program

Curasight has a long-term incentive program covering the financial years 2022-2025 with a total of 956,770 warrants covering the Company's Board of Directors, Executive Management and other key employees. For the Board of Directors, a total of 229,230 warrants are issued entitling the warrant holders to subscribe for up to a total of DKK 11,461.50 nominally worth of shares in the Company. The warrants are allocated between Lars Trolle (dept. chairman of the Board of Directors), Charlotte Vedel (member of the Board of Directors) and Kirsten Aarup Drejer (Chair of the Board of Directors).

For the Executive Management and other key employees of the Company, a total of 727,540 warrants are issued entitling the warrant holders to subscribe for up to a total of DKK 36,377.00 nominally worth of shares in the Company. The warrants are allocated between Ulrich Krasinikoff (CEO), Andreas Kjaer (CSO), Hanne Damgaard Jensen (CDO), Nic Gillings (Head of Quality Assurance and Regulatory Affairs) and Jacob Madsen (Director CMC).

On July 30, 2024, Curasight re-issued a total of 59,132 (previously lapsed) warrants with rights to subscribe for

a total of DKK 2,956.60 nominally worth of shares in the Company. 42,460 warrants will be re-issued as part of the ordinary incentive program covering the Executive Management and key employees of the Company. 16,672 warrants will be re-issued and allocated to Chair of the Board of Directors Kirsten Drejer as part of the ordinary incentive program covering the Board of Directors of the Company.

Risks

A number of risk factors can affect Curasight's operations. It is therefore of great importance to consider relevant risks in addition to the Company's growth opportunities. For a detailed description of the risks attributable to the Company and its shares, please refer to the disclosure document published by the Company in 2025. The document is available on Curasight's website: www.curasight.com/investor/rights-issue-2025.

Accounting policy

The year-end report is presented in accordance with the provisions of the Danish Financial Statements Act (Årsregnskabsloven) for enterprises in reporting class B with application of provisions for a higher reporting class.

Auditor's review

The year-end report has not been reviewed by the Company's auditor.

Proposal for disposition of Curasight's results

The Board and the CEO propose that no dividend be paid for the financial year 2024-01-01 – 2024-12-31.

Annual General Meeting and availability of the Annual Report 2024

The Annual General Meeting will be held on March 25, 2026 in Copenhagen. The annual report will be available on the Company's website (www.curasight.com) no later than two weeks before the Annual General Meeting.

Financial calendar

AGM 2026	March 25, 2026
Interim report Q1 2026	May 28, 2026
Interim report Q2 2026	August 27, 2026
Interim report Q3 2026	November 26, 2026

Financial statements

Income statement

Operating loss before tax for the fourth quarter of 2025 amounted to kDKK -16,203 (kDKK -11,924). Operating loss before tax for 2025 amounted to kDKK -58,730 (kDKK -40,367).

Loss before depreciation, amortisation and impairments for the fourth quarter amounted to kDKK -16,000 (kDKK -11,720) of which staff expenses was kDKK -1,423 (kDKK -1,510). Loss before depreciation, amortisation and impairments for 2025 amounted to kDKK -54,778 (kDKK -39,553) of which staff expenses was kDKK -5,103 (kDKK -6,822).

Loss before depreciation, amortisation and impairments comprise of revenue, clinical expenses, patent expenses, staff expenses and other business expenses.

Balance sheet


Per December 31, 2025, the Company's balance sheet amounted to kDKK 50,055 (23,688).

The assets consisted primarily of acquired IP-rights totaling kDKK 6,013 related to the development of uTRACE® and uTREAT®, total receivables of kDKK 8,053 and cash amounted to kDKK 35,912. The equity and liabilities consisted primarily of an equity totaling kDKK 18,560 and short-term debt of kDKK 31,495.

Cash flow

Curasight's total cash flow in Q4 2025 amounted to kDKK 20,012. Curasight's cash flow from operating activities in October – December 2025 amounted to kDKK -10,328.

Cash as of December 31, 2025, was kDKK 35,912 (kDKK 10,011).



Income statement

(kDKK)	Q4 2025*	Q4 2024*	Q1-Q4 2025	Q1-Q4 2024
Gross loss	-14,577	-10,210	-49,676	-32,731
Staff expenses	-1,423	-1,510	-5,102	-6,822
Loss before depreciation, amortisation, write-downs and impairment losses	-16,000	-11,720	-54,778	-39,553
Depreciation, amortisation and impairment of intangible assets and property, plant and equipment	-203	-203	-814	-814
Operating loss	-16,203	-11,924	-55,592	-40,367
Net financial income	42	223	42	264
Net financial expenses	-525	-633	-3,180	-2,233
Loss before tax	-16,686	-12,334	-58,730	-42,336
Tax on loss for the period	1,375	1,375	5,500	5,500
Loss for the period	-15,311	-10,959	-53,230	-36,836

*) Unaudited figures

Balance sheet, Assets

(kDKK)	2025-12-31	2024-12-31
Acquired patents	6,013	6,827
Intangible assets	6,013	6,827
Deposits	77	51
Total investments	77	51
Total non-current assets	6,090	6,878
Other receivables	2,553	1,299
Income tax receivables	5,500	5,500
Total receivables	8,053	6,799
Cash at bank and in hand	35,912	10,011
Total current assets	43,965	16,810
Assets	50,055	23,688

Balance sheet—Liabilities and equity

(kDKK)	2025-12-31	2024-12-31
Share capital	2,396	1,057
Retained earnings	15,540	6,654
Equity	17,936	7,711
Trade payables	6,123	4,155
Other payables	25,060	10,922
Debt	936	900
Short term-debt	32,119	15,977
Debt	32,119	15,977
Liabilities and equity	50,055	23,688

Equity—Q4* 2025

(kDKK)	Share capital	Share account premium	Retained earnings	Total
Change in equity Q4 2025				
Equity at 30 September 2025	2,293	0	15,178	17,471
Net profit/loss for the year	0	0	-15,311	-15,311
Capital Increase	103	0	16,299	16,402
Equity at 31 December 2025	2,396	0	15,540	17,936

*) Unaudited figures

Equity—Q4* 2024

(kDKK)	Share capital	Share account premium	Retained earnings	Total
Change in equity: Q4 2024				
Equity at 30 September 2024	1,034	0	12,272	13,305
Net profit/loss for the period	0	0	-10,959	-10,959
Capital Increase	23	0	5,341	5,364
Equity at 31 December 2024	1,057	0	6,654	7,711

Equity—FY 2025

(kDKK)	Share capital	Share account premium	Retained earnings	Total
Change in equity: Q1-Q4 2025				
Equity at 1 January 2025	1,057	0	6,654	7,711
Net profit/loss for the year	0	0	-53,230	-53,230
Capital Increase	1,339	0	62,116	63,455
Equity at 31 December 2025	2,396	0	15,540	17,936

*) Unaudited figures

Equity—FY 2024

(kDKK)	Share capital	Share account premium	Retained earnings	Total
Change in equity Q1-Q4 2024				
Equity at 1 January 2024	995	0	30,388	31,383
Net profit/loss for the year	0	0	-36,836	-36,836
Capital Increase	62	0	13,102	13,164
Equity at 31 December 2024	1,057	0	6,654	7,711

*) Unaudited figures

Cash flow statement

(kDKK)	Q4 2025*	Q4 2024*	Q1-Q4 2025	Q1-Q4 2024
Loss for the period	-15,311	-10,959	-53,230	-36,836
Adjustments	2,620	-762	-1,506	-2,717
Change in working capital	1,842	1,901	657	944
Cash flow from operating activities before net financials	-10,849	-9,820	-54,079	-38,609
Interest expenses and similar expenses paid	-854	107	-3,139	-1,046
Income tax received/paid	1,375	5,500	5,500	5,500
Cash flow from operating activities	-10,328	-4,213	-51,718	-34,155
Change in deposits	26	0	26	0
Proceeds from loans	13,911	922	14,138	10,922
Capital increase	16,402	5,364	63,455	13,164
Cash flows from investing activities	30,339	6,286	77,619	24,086
Total cash flows for the period	20,011	2,073	25,901	-10,069
Cash, beginning of the period	15,899	7,938	10,011	20,080
Cash, end of the period	35,912	10,011	35,912	10,011
Cash, end of the period	35,912	10,011	35,912	10,011
Total	35,912	10,011	35,912	10,011

*) Unaudited figures

Statement by the Board of Directors

The Board of Directors provide their assurance that the year-end report provides a fair and true overview of the Company's operations, financial position, and results.

København N, February 26, 2026
Curasight A/S

Board of Directors

Kirsten Drejer
Chair of the Board

Lars Trolle
Dept. chair of the Board

Charlotte Vedel
Board member

Andreas Kjær
Board member

Ulrich Krasilnikoff
Board member and CEO

Contact information
Curasight A/S
Ole Maaløes Vej 3
2200 Copenhagen, Denmark
Email: info@curasight.com
Phone: +4522830160

Curasight's team are pioneers behind the novel uPAR Theranostics technology. The technology minimizes irradiation of healthy tissue by combining the targeted uTREAT[®] radiation therapy, with the precise uTRACE[®] diagnostics.